TacticScaleWhat Neurocrine Biosciences Does & How It Makes Money (NBIX)
Updated October 2026 · reflects Neurocrine Biosciences's latest reported financials
San Diego biopharma company developing neurological, psychiatric and endocrine medicines. Neurocrine makes money mainly by selling its approved prescription medicines in the United States and internationally.
How Neurocrine Biosciences makes money
Neurocrine makes money mainly by selling its approved prescription medicines in the United States and internationally. It also has license and collaboration agreements with drugmakers such as AbbVie, Takeda, Sanofi and Tanabe Pharma.
What Neurocrine Biosciences does
Neurocrine Biosciences was founded in 1992 and is based in San Diego. It focuses on neurological, psychiatric, endocrine and immunological disorders. Its lead product, INGREZZA, treats tardive dyskinesia and chorea associated with Huntington's disease. CRENESSITY, ALKINDI and Efmody address congenital adrenal hyperplasia and related hormone needs. Orilissa and Oriahnn serve women's health patients with endometriosis and uterine fibroids. The company's pipeline covers a wide range of brain and metabolic conditions. It includes osavampator and NBI-1070770 for major depressive disorder, NBI-1117568 for schizophrenia and bipolar mania, and NBI-1117567 for Alzheimer's disease. Other candidates target epilepsy, movement disorders, congenital adrenal hyperplasia and obesity. Neurocrine also works through partnerships with Nxera, Takeda, Xenon, Voyager, Sanofi, Tanabe Pharma and AbbVie, which extend its research reach beyond its own labs.
Products & services
- INGREZZA
- CRENESSITY
- Orilissa
- Oriahnn
- ALKINDI
- Efmody
What is Neurocrine Biosciences worth?
On an owner-earnings DCF, Neurocrine Biosciences's most-likely value is about $349 versus a recent price near $142 (145% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$96) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Biogen (BIIB) · Supernus Pharmaceuticals (SUPN) · ACADIA Pharmaceuticals (ACAD) · AbbVie (ABBV)